{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T07:27:26Z","timestamp":1794554846265,"version":"4.9.1"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2023,7,15]],"date-time":"2023-07-15T00:00:00Z","timestamp":1689379200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,7,15]],"date-time":"2023-07-15T00:00:00Z","timestamp":1689379200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100005677","name":"Jos\u00e9 Carreras Leuk\u00e4mie-Stiftung","doi-asserted-by":"publisher","award":["08 R\/2020"],"award-info":[{"award-number":["08 R\/2020"]}],"id":[{"id":"10.13039\/501100005677","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2023,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    In a registry-based analysis of 135 patients with \u201cmyeloid\/lymphoid neoplasms with eosinophilia and tyrosine kinase gene fusions\u201d (MLN-TK;\n                    <jats:italic>FIP1L1::PDGFRA<\/jats:italic>\n                    ,\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u200978;\n                    <jats:italic>PDGFRB<\/jats:italic>\n                    , diverse fusions,\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u200926;\n                    <jats:italic>FGFR1<\/jats:italic>\n                    , diverse,\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u20099;\n                    <jats:italic>JAK2<\/jats:italic>\n                    , diverse,\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u200911;\n                    <jats:italic>ETV6::ABL1<\/jats:italic>\n                    ,\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u200911), we sought to evaluate the disease-defining characteristics. In 81\/135 (60%) evaluable patients, hypereosinophilia (&gt;1.5\u2009\u00d7\u200910\n                    <jats:sup>9<\/jats:sup>\n                    \/l) was observed in 40\/44 (91%)\n                    <jats:italic>FIP1L1::PDGFRA<\/jats:italic>\n                    and 7\/7 (100%)\u00a0\n                    <jats:italic>ETV6::ABL1<\/jats:italic>\n                    positive patients but only in 13\/30 (43%) patients with\n                    <jats:italic>PDGFRB<\/jats:italic>\n                    ,\n                    <jats:italic>FGFR1,<\/jats:italic>\n                    and\n                    <jats:italic>JAK2<\/jats:italic>\n                    fusion genes while 9\/30 (30%) patients had no eosinophilia. Monocytosis &gt;1\u2009\u00d7\u200910\n                    <jats:sup>9<\/jats:sup>\n                    \/l was identified in 27\/81 (33%) patients, most frequently in association with hypereosinophilia (23\/27, 85%). Overall, a blast phase (BP) was diagnosed in 38\/135 (28%) patients (myeloid, 61%; lymphoid, 39%), which was at extramedullary sites in 18 (47%) patients. The comparison between patients with\n                    <jats:italic>PDGFRA<\/jats:italic>\n                    \/\n                    <jats:italic>PDGFRB<\/jats:italic>\n                    vs.\n                    <jats:italic>FGFR1<\/jats:italic>\n                    ,\n                    <jats:italic>JAK2,<\/jats:italic>\n                    and\n                    <jats:italic>ETV6::ABL1<\/jats:italic>\n                    fusion genes revealed a similar occurrence of primary BP (17\/104, 16% vs. 8\/31 26%,\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.32), a lower frequency (5\/87, 6% vs. 8\/23, 35%,\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.003) of and a later progression\u00a0(median 87 vs. 19 months,\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.053) into secondary BP, and a better overall survival from diagnosis of BP (17.1 vs. 1.7 years,\n                    <jats:italic>p<\/jats:italic>\n                    \u2009&lt;\u20090.0008). We conclude that hypereosinophilia with or without monocytosis and various phenotypes of BP occur at variable frequencies in MLN-TK.\n                  <\/jats:p>","DOI":"10.1038\/s41375-023-01958-1","type":"journal-article","created":{"date-parts":[[2023,7,15]],"date-time":"2023-07-15T16:19:05Z","timestamp":1689437945000},"page":"1860-1867","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":45,"title":["Myeloid\/lymphoid neoplasms with eosinophilia and tyrosine kinase gene fusions: reevaluation of the defining characteristics in a registry-based cohort"],"prefix":"10.1038","volume":"37","author":[{"given":"Georgia","family":"Metzgeroth","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4524-037X","authenticated-orcid":false,"given":"Laurenz","family":"Steiner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Naumann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0767-1504","authenticated-orcid":false,"given":"Johannes","family":"L\u00fcbke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Kreil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice","family":"Fabarius","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6333-5049","authenticated-orcid":false,"given":"Claudia","family":"Haferlach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Torsten","family":"Haferlach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolf-Karsten","family":"Hofmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5481-2555","authenticated-orcid":false,"given":"Nicholas C. P.","family":"Cross","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juliana","family":"Schwaab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7718-6507","authenticated-orcid":false,"given":"Andreas","family":"Reiter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,7,15]]},"reference":[{"key":"1958_CR1","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1038\/s41375-022-01613-1","volume":"36","author":"JD Khoury","year":"2022","unstructured":"Khoury JD, Solary E, Abla O, Akkari Y, Alaggio R, Apperley JF, et al. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic\/Dendritic Neoplasms. Leukemia. 2022;36:1703\u201319.","journal-title":"Leukemia."},{"key":"1958_CR2","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1182\/blood.2022015850","volume":"140","author":"DA Arber","year":"2022","unstructured":"Arber DA, Orazi A, Hasserjian RP, Borowitz MJ, Calvo KR, Kvasnicka HM, et al. International consensus classification of myeloid neoplasms and acute leukemias: integrating morphologic, clinical, and genomic data. Blood. 2022;140:1200\u201328.","journal-title":"Blood."},{"key":"1958_CR3","unstructured":"Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. 4th ed. WHO press; 2016."},{"key":"1958_CR4","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1182\/blood-2016-10-695973","volume":"129","author":"A Reiter","year":"2017","unstructured":"Reiter A, Gotlib J. Myeloid neoplasms with eosinophilia. Blood. 2017;129:704\u201314.","journal-title":"Blood."},{"key":"1958_CR5","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1007\/s00277-017-3067-x","volume":"96","author":"M Jawhar","year":"2017","unstructured":"Jawhar M, Naumann N, Schwaab J, Baurmann H, Casper J, Dang TA, et al. Imatinib in myeloid\/lymphoid neoplasms with eosinophilia and rearrangement of PDGFRB in chronic or blast phase. Ann Hematol. 2017;96:1463\u201370.","journal-title":"Ann Hematol"},{"key":"1958_CR6","doi-asserted-by":"publisher","first-page":"1999","DOI":"10.1038\/leu.2008.287","volume":"22","author":"J Gotlib","year":"2008","unstructured":"Gotlib J, Cools J. Five years since the discovery of FIP1L1-PDGFRA: what we have learned about the fusion and other molecularly defined eosinophilias. Leukemia. 2008;22:1999\u20132010.","journal-title":"Leukemia."},{"key":"1958_CR7","doi-asserted-by":"publisher","first-page":"2254","DOI":"10.1038\/leu.2013.129","volume":"27","author":"G Metzgeroth","year":"2013","unstructured":"Metzgeroth G, Schwaab J, Gosenca D, Fabarius A, Haferlach C, Hochhaus A, et al. Long-term follow-up of treatment with imatinib in eosinophilia-associated myeloid\/lymphoid neoplasms with PDGFR rearrangements in blast phase. Leukemia. 2013;27:2254\u20136.","journal-title":"Leukemia."},{"key":"1958_CR8","doi-asserted-by":"publisher","first-page":"3574","DOI":"10.1182\/blood-2014-02-555607","volume":"123","author":"CY Cheah","year":"2014","unstructured":"Cheah CY, Burbury K, Apperley JF, Huguet F, Pitini V, Gardembas M, et al. Patients with myeloid malignancies bearing PDGFRB fusion genes achieve durable long-term remissions with imatinib. Blood. 2014;123:3574\u20137.","journal-title":"Blood."},{"key":"1958_CR9","doi-asserted-by":"publisher","first-page":"2662","DOI":"10.1158\/0008-5472.CAN-04-4263","volume":"65","author":"A Reiter","year":"2005","unstructured":"Reiter A, Walz C, Watmore A, Schoch C, Blau I, Schlegelberger B, et al. The t(8;9)(p22;p24) is a recurrent abnormality in chronic and acute leukemia that fuses PCM1 to JAK2. Cancer Res. 2005;65:2662\u20137.","journal-title":"Cancer Res."},{"key":"1958_CR10","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1007\/s00277-014-2221-y","volume":"94","author":"J Schwaab","year":"2015","unstructured":"Schwaab J, Knut M, Haferlach C, Metzgeroth G, Horny HP, Chase A, et al. Limited duration of complete remission on ruxolitinib in myeloid neoplasms with PCM1-JAK2 and BCR-JAK2 fusion genes. Ann Hematol. 2015;94:233\u20138.","journal-title":"Ann Hematol"},{"key":"1958_CR11","doi-asserted-by":"publisher","first-page":"1880","DOI":"10.1093\/annonc\/mdy173","volume":"29","author":"S Verstovsek","year":"2018","unstructured":"Verstovsek S, Subbiah V, Masarova L, Yin CC, Tang G, Manshouri T, et al. Treatment of the myeloid\/lymphoid neoplasm with FGFR1 rearrangement with FGFR1 inhibitor. Ann Oncol. 2018;29:1880\u20132.","journal-title":"Ann Oncol"},{"key":"1958_CR12","doi-asserted-by":"publisher","first-page":"e661","DOI":"10.1093\/oncolo\/oyac072","volume":"27","author":"HG Kaplan","year":"2022","unstructured":"Kaplan HG, Jin R, Bifulco CB, Scanlan JM, Corwin DR. PCM1-JAK2 fusion tyrosine kinase gene-related neoplasia: a systematic review of the clinical literature. Oncologist. 2022;27:e661\u2013e70.","journal-title":"Oncologist"},{"key":"1958_CR13","doi-asserted-by":"publisher","first-page":"1927","DOI":"10.1007\/s00277-015-2451-7","volume":"94","author":"E Rumi","year":"2015","unstructured":"Rumi E, Milosevic JD, Selleslag D, Casetti I, Lierman E, Pietra D, et al. Efficacy of ruxolitinib in myeloid neoplasms with PCM1-JAK2 fusion gene. Ann Hematol. 2015;94:1927\u20138.","journal-title":"Ann Hematol"},{"key":"1958_CR14","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1182\/blood-2012-06-433821","volume":"120","author":"E Lierman","year":"2012","unstructured":"Lierman E, Selleslag D, Smits S, Billiet J, Vandenberghe P. Ruxolitinib inhibits transforming JAK2 fusion proteins in vitro and induces complete cytogenetic remission in t(8;9)(p22;p24)\/PCM1-JAK2-positive chronic eosinophilic leukemia. Blood. 2012;120:1529\u201331.","journal-title":"Blood."},{"key":"1958_CR15","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1038\/sj.leu.2404662","volume":"21","author":"G Metzgeroth","year":"2007","unstructured":"Metzgeroth G, Walz C, Score J, Siebert R, Schnittger S, Haferlach C, et al. Recurrent finding of the FIP1L1-PDGFRA fusion gene in eosinophilia-associated acute myeloid leukemia and lymphoblastic T-cell lymphoma. Leukemia. 2007;21:1183\u20138.","journal-title":"Leukemia"},{"key":"1958_CR16","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1002\/ajh.25825","volume":"95","author":"J Schwaab","year":"2020","unstructured":"Schwaab J, Naumann N, Luebke J, Jawhar M, Somervaille TCP, Williams MS, et al. Response to tyrosine kinase inhibitors in myeloid neoplasms associated with PCM1-JAK2, BCR-JAK2 and ETV6-ABL1 fusion genes. Am J Hematol. 2020;95:824\u201333.","journal-title":"Am J Hematol"},{"key":"1958_CR17","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.cancergencyto.2004.06.001","volume":"157","author":"CA Tirado","year":"2005","unstructured":"Tirado CA, Sebastian S, Moore JO, Gong JZ, Goodman BK. Molecular and cytogenetic characterization of a novel rearrangement involving chromosomes 9, 12, and 17 resulting in ETV6 (TEL) and ABL fusion. Cancer Genet Cytogenet. 2005;157:74\u20137.","journal-title":"Cancer Genet Cytogenet"},{"key":"1958_CR18","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1007\/s00277-012-1431-4","volume":"91","author":"MH Zhou","year":"2012","unstructured":"Zhou MH, Gao L, Jing Y, Xu YY, Ding Y, Wang N, et al. Detection of ETV6 gene rearrangements in adult acute lymphoblastic leukemia. Ann Hematol. 2012;91:1235\u201343.","journal-title":"Ann Hematol"},{"key":"1958_CR19","doi-asserted-by":"publisher","first-page":"e646","DOI":"10.1097\/HS9.0000000000000646","volume":"5","author":"P Valent","year":"2021","unstructured":"Valent P, Akin C, Hartmann K, Alvarez-Twose I, Brockow K, Hermine O, et al. Updated diagnostic criteria and classification of mast cell disorders: a consensus proposal. Hemasphere. 2021;5:e646.","journal-title":"Hemasphere"},{"key":"1958_CR20","doi-asserted-by":"publisher","first-page":"2812","DOI":"10.1182\/blood.V126.23.2812.2812","volume":"126","author":"S Kreil","year":"2015","unstructured":"Kreil S, Ad\u00e8s L, Bommer M, Stegelmann F, Ethell ME, Lubking A, et al. Limited efficacy of ponatinib in myeloproliferative neoplasms associated with FGFR1 fusion genes. Blood. 2015;126:2812.","journal-title":"Blood"},{"key":"1958_CR21","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1182\/blood-2021-148103","volume":"138","author":"G Gotlib","year":"2021","unstructured":"Gotlib G, Kiladjian J, Vannucchi A, Rambaldi A, Reiter A, Shomali W, et al. A phase 2 study of pemigatinib (FIGHT-203; INCB054828) in patients with myeloid\/lymphoid neoplasms (MLNs) with fibroblast growth factor receptor 1 (FGFR1) rearrangement (MLN FGFR1). Blood. 2021;138:385.","journal-title":"Blood"},{"key":"1958_CR22","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1080\/16078454.2020.1854493","volume":"26","author":"M Chen","year":"2021","unstructured":"Chen M, Wang K, Cai X, Zhang X, Chao H, Chen S, et al. Myeloid\/lymphoid neoplasm with CEP110-FGFR1 fusion: An analysis of 16 cases show common features and poor prognosis. Hematology. 2021;26:153\u20139.","journal-title":"Hematology."},{"key":"1958_CR23","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1007\/s00277-013-1695-3","volume":"92","author":"V Patterer","year":"2013","unstructured":"Patterer V, Schnittger S, Kern W, Haferlach T, Haferlach C. Hematologic malignancies with PCM1-JAK2 gene fusion share characteristics with myeloid and lymphoid neoplasms with eosinophilia and abnormalities of PDGFRA, PDGFRB, and FGFR1. Ann Hematol. 2013;92:759\u201369.","journal-title":"Ann Hematol"},{"key":"1958_CR24","doi-asserted-by":"publisher","first-page":"1672","DOI":"10.1080\/10428194.2017.1397663","volume":"59","author":"P Strati","year":"2018","unstructured":"Strati P, Tang G, Duose DY, Mallampati S, Luthra R, Patel KP, et al. Myeloid\/lymphoid neoplasms with FGFR1 rearrangement. Leuk Lymphoma. 2018;59:1672\u20136.","journal-title":"Leuk Lymphoma"},{"key":"1958_CR25","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1038\/s41409-021-01553-x","volume":"57","author":"JC Hernandez-Boluda","year":"2022","unstructured":"Hernandez-Boluda JC, Pereira A, Zinger N, Gras L, Martino R, Nikolousis E, et al. Allogeneic hematopoietic cell transplantation in patients with myeloid\/lymphoid neoplasm with FGFR1-rearrangement: a study of the Chronic Malignancies Working Party of EBMT. Bone Marrow Transplant. 2022;57:416\u201322.","journal-title":"Bone Marrow Transplant"},{"key":"1958_CR26","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1182\/hematology.2022000368","volume":"2022","author":"J Gotlib","year":"2022","unstructured":"Gotlib J. Available and emerging therapies for bona fide advanced systemic mastocytosis and primary eosinophilic neoplasms. Hematology Am Soc Hematol Educ Program. 2022;2022:34\u201346.","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"1958_CR27","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1080\/10245332.2018.1446279","volume":"23","author":"K Umino","year":"2018","unstructured":"Umino K, Fujiwara SI, Ikeda T, Toda Y, Ito S, Mashima K, et al. Clinical outcomes of myeloid\/lymphoid neoplasms with fibroblast growth factor receptor-1 (FGFR1) rearrangement. Hematology. 2018;23:470\u20137.","journal-title":"Hematology."},{"key":"1958_CR28","doi-asserted-by":"publisher","first-page":"a004838","DOI":"10.1101\/mcs.a004838","volume":"6","author":"EJ Barnes","year":"2020","unstructured":"Barnes EJ, Leonard J, Medeiros BC, Druker BJ, Tognon CE. Functional characterization of two rare BCR-FGFR1(+) leukemias. Cold Spring Harb Mol Case Stud. 2020;6:a004838.","journal-title":"Cold Spring Harb Mol Case Stud"},{"key":"1958_CR29","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1309\/AJCPMORR5Z2IKCEM","volume":"144","author":"F Vega","year":"2015","unstructured":"Vega F, Medeiros LJ, Bueso-Ramos CE, Arboleda P, Miranda RN. Hematolymphoid neoplasms associated with rearrangements of PDGFRA, PDGFRB, and FGFR1. Am J Clin Pathol. 2015;144:377\u201392.","journal-title":"Am J Clin Pathol"},{"key":"1958_CR30","doi-asserted-by":"publisher","first-page":"3136","DOI":"10.1182\/bloodadvances.2020002308","volume":"4","author":"M Kasbekar","year":"2020","unstructured":"Kasbekar M, Nardi V, Dal Cin P, Brunner AM, Burke M, Chen YB, et al. Targeted FGFR inhibition results in a durable remission in an FGFR1-driven myeloid neoplasm with eosinophilia. Blood Adv. 2020;4:3136\u201340.","journal-title":"Blood Adv"},{"key":"1958_CR31","doi-asserted-by":"publisher","first-page":"3778","DOI":"10.1182\/blood.V98.13.3778","volume":"98","author":"A Demiroglu","year":"2001","unstructured":"Demiroglu A, Steer EJ, Heath C, Taylor K, Bentley M, Allen SL, et al. The t(8;22) in chronic myeloid leukemia fuses BCR to FGFR1: transforming activity and specific inhibition of FGFR1 fusion proteins. Blood. 2001;98:3778\u201383.","journal-title":"Blood."},{"key":"1958_CR32","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1038\/sj.thj.6200201","volume":"3","author":"M Pini","year":"2002","unstructured":"Pini M, Gottardi E, Scaravaglio P, Giugliano E, Libener R, Baraldi A, et al. A fourth case of BCR-FGFR1 positive CML-like disease with t(8;22) translocation showing an extensive deletion on the derivative chromosome 8p. Hematol J. 2002;3:315\u20136.","journal-title":"Hematol J"},{"key":"1958_CR33","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.cancergencyto.2008.07.002","volume":"186","author":"SG Lee","year":"2008","unstructured":"Lee SG, Park TS, Lee ST, Lee KA, Song J, Kim J, et al. Rare translocations involving chromosome band 8p11 in myeloid neoplasms. Cancer Genet Cytogenet. 2008;186:127\u20139.","journal-title":"Cancer Genet Cytogenet"},{"key":"1958_CR34","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1002\/gcc.20588","volume":"47","author":"S Richebourg","year":"2008","unstructured":"Richebourg S, Theisen O, Plantier I, Parry A, Soenen-Cornu V, Lepelley P, et al. Chronic myeloproliferative disorder with t(8;22)(p11;q11) can mime clonal cytogenetic evolution of authentic chronic myelogeneous leukemia. Genes Chromosomes Cancer. 2008;47:915\u20138.","journal-title":"Genes Chromosomes Cancer."},{"key":"1958_CR35","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1002\/ajh.21631","volume":"85","author":"MM Patnaik","year":"2010","unstructured":"Patnaik MM, Gangat N, Knudson RA, Keefe JG, Hanson CA, Pardanani A, et al. Chromosome 8p11.2 translocations: prevalence, FISH analysis for FGFR1 and MYST3, and clinicopathologic correlates in a consecutive cohort of 13 cases from a single institution. Am J Hematol. 2010;85:238\u201342.","journal-title":"Am J Hematol"},{"key":"1958_CR36","doi-asserted-by":"publisher","first-page":"e282","DOI":"10.1016\/j.leukres.2010.05.009","volume":"34","author":"C Baldazzi","year":"2010","unstructured":"Baldazzi C, Iacobucci I, Luatti S, Ottaviani E, Marzocchi G, Paolini S, et al. B-cell acute lymphoblastic leukemia as evolution of a 8p11 myeloproliferative syndrome with t(8;22)(p11;q11) and BCR-FGFR1 fusion gene. Leuk Res. 2010;34:e282\u20135.","journal-title":"Leuk Res"},{"key":"1958_CR37","doi-asserted-by":"publisher","first-page":"e30","DOI":"10.1016\/j.leukres.2010.12.014","volume":"35","author":"SY Kim","year":"2011","unstructured":"Kim SY, Oh B, She CJ, Kim HK, Jeon YK, Shin MG, et al. 8p11 Myeloproliferative syndrome with BCR-FGFR1 rearrangement presenting with T-lymphoblastic lymphoma and bone marrow stromal cell proliferation: a case report and review of the literature. Leuk Res. 2011;35:e30\u20134.","journal-title":"Leuk Res"},{"key":"1958_CR38","doi-asserted-by":"publisher","first-page":"e151","DOI":"10.1016\/j.leukres.2011.05.013","volume":"35","author":"JJ Wakim","year":"2011","unstructured":"Wakim JJ, Tirado CA, Chen W, Collins R. t(8;22)\/BCR-FGFR1 myeloproliferative disorder presenting as B-acute lymphoblastic leukemia: report of a case treated with sorafenib and review of the literature. Leuk Res. 2011;35:e151\u20133.","journal-title":"Leuk Res"},{"key":"1958_CR39","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1002\/pbc.23404","volume":"59","author":"M Dolan","year":"2012","unstructured":"Dolan M, Cioc A, Cross NC, Neglia JP, Tolar J. Favorable outcome of allogeneic hematopoietic cell transplantation for 8p11 myeloproliferative syndrome associated with BCR-FGFR1 gene fusion. Pediatr Blood Cancer. 2012;59:194\u20136.","journal-title":"Pediatr Blood Cancer"},{"key":"1958_CR40","first-page":"620967","volume":"2012","author":"K Haslam","year":"2012","unstructured":"Haslam K, Langabeer SE, Kelly J, Coen N, O'Connell NM, Conneally E. Allogeneic hematopoietic stem cell transplantation for a BCR-FGFR1 myeloproliferative neoplasm presenting as acute lymphoblastic leukemia. Case Rep Hematol. 2012;2012:620967.","journal-title":"Case Rep Hematol"},{"key":"1958_CR41","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1159\/000341289","volume":"129","author":"S Morishige","year":"2013","unstructured":"Morishige S, Oku E, Takata Y, Kimura Y, Arakawa F, Seki R, et al. A case of 8p11 myeloproliferative syndrome with BCR-FGFR1 gene fusion presenting with trilineage acute leukemia\/lymphoma, successfully treated by cord blood transplantation. Acta Haematol. 2013;129:83\u20139.","journal-title":"Acta Haematol"},{"key":"1958_CR42","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1159\/000345727","volume":"129","author":"M Shimanuki","year":"2013","unstructured":"Shimanuki M, Sonoki T, Hosoi H, Watanuki J, Murata S, Mushino T, et al. Acute leukemia showing t(8;22)(p11;q11), myelodysplasia, CD13\/CD33\/CD19 expression and immunoglobulin heavy chain gene rearrangement. Acta Haematol. 2013;129:238\u201342.","journal-title":"Acta Haematol."},{"key":"1958_CR43","doi-asserted-by":"publisher","first-page":"bcr2013008834","DOI":"10.1136\/bcr-2013-008834","volume":"2013","author":"A Matikas","year":"2013","unstructured":"Matikas A, Tzannou I, Oikonomopoulou D, Bakiri M. A case of acute myelogenous leukaemia characterised by the BCR-FGFR1 translocation. BMJ Case Rep. 2013;2013:bcr2013008834.","journal-title":"BMJ Case Rep"},{"key":"1958_CR44","doi-asserted-by":"publisher","first-page":"708","DOI":"10.6004\/jnccn.2016.0072","volume":"14","author":"W Wang","year":"2016","unstructured":"Wang W, Tang G, Kadia T, Lu X, Li Y, Huang L, et al. Cytogenetic evolution associated with disease progression in hematopoietic neoplasms With t(8;22)(p11;q11)\/BCR-FGFR1 rearrangement. J Natl Compr Canc Netw. 2016;14:708\u201311.","journal-title":"J Natl Compr Canc Netw"},{"key":"1958_CR45","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1038\/leu.2015.136","volume":"30","author":"MS Khodadoust","year":"2016","unstructured":"Khodadoust MS, Luo B, Medeiros BC, Johnson RC, Ewalt MD, Schalkwyk AS, et al. Clinical activity of ponatinib in a patient with FGFR1-rearranged mixed-phenotype acute leukemia. Leukemia. 2016;30:947\u201350.","journal-title":"Leukemia."},{"key":"1958_CR46","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1111\/ejh.12957","volume":"99","author":"N Landberg","year":"2017","unstructured":"Landberg N, Dreimane A, Rissler M, Billstrom R, Agerstam H. Primary cells in BCR\/FGFR1-positive 8p11 myeloproliferative syndrome are sensitive to dovitinib, ponatinib, and dasatinib. Eur J Haematol. 2017;99:442\u20138.","journal-title":"Eur J Haematol"},{"key":"1958_CR47","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/j.humpath.2017.05.008","volume":"65","author":"X Montenegro-Garreaud","year":"2017","unstructured":"Montenegro-Garreaud X, Miranda RN, Reynolds A, Tang G, Wang SA, Yabe M, et al. Myeloproliferative neoplasms with t(8;22)(p11.2;q11.2)\/BCR-FGFR1: a meta-analysis of 20 cases shows cytogenetic progression with B-lymphoid blast phase. Hum Pathol. 2017;65:147\u201356.","journal-title":"Hum Pathol"},{"key":"1958_CR48","first-page":"1449","volume":"16","author":"JJ Liu","year":"2018","unstructured":"Liu JJ, Meng L. 8p11 Myeloproliferative syndrome with t(8;22)(p11;q11): a case report. Exp Ther Med. 2018;16:1449\u201353.","journal-title":"Exp Ther Med"},{"key":"1958_CR49","first-page":"5724960","volume":"2018","author":"P Villafuerte-Gutierrez","year":"2018","unstructured":"Villafuerte-Gutierrez P, Lopez Rubio M, Herrera P, Arranz E. A case of myeloproliferative neoplasm with BCR-FGFR1 rearrangement: favorable outcome after haploidentical allogeneic transplantation. Case Rep Hematol. 2018;2018:5724960.","journal-title":"Case Rep Hematol"},{"key":"1958_CR50","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1038\/s41409-018-0287-1","volume":"54","author":"Y Konishi","year":"2019","unstructured":"Konishi Y, Kondo T, Nakao K, Asagoe K, Otsuka Y, Nishikori M, et al. Allogeneic hematopoietic stem cell transplantation for 8p11 myeloproliferative syndrome with BCR-FGFR1 gene rearrangement: a case report and literature review. Bone Marrow Transplant. 2019;54:326\u20139.","journal-title":"Bone Marrow Transplant"},{"key":"1958_CR51","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1038\/s41375-018-0342-3","volume":"33","author":"NCP Cross","year":"2018","unstructured":"Cross NCP, Hoade Y, Tapper WJ, Carreno-Tarragona G, Fanelli T, Jawhar M, et al. Recurrent activating STAT5B N642H mutation in myeloid neoplasms with eosinophilia. Leukemia. 2018;33:415\u201325.","journal-title":"Leukemia."},{"key":"1958_CR52","doi-asserted-by":"publisher","first-page":"2271","DOI":"10.1038\/leu.2017.240","volume":"31","author":"M Jawhar","year":"2017","unstructured":"Jawhar M, Naumann N, Knut M, Score J, Ghazzawi M, Schneider B, et al. Cytogenetically cryptic ZMYM2-FLT3 and DIAPH1-PDGFRB gene fusions in myeloid neoplasms with eosinophilia. Leukemia. 2017;31:2271\u20133.","journal-title":"Leukemia."},{"key":"1958_CR53","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1038\/s41375-019-0632-4","volume":"34","author":"HC Kluin-Nelemans","year":"2020","unstructured":"Kluin-Nelemans HC, Reiter A, Illerhaus A, van Anrooij B, Hartmann K, Span LFR, et al. Prognostic impact of eosinophils in mastocytosis: analysis of 2350 patients collected in the ECNM Registry. Leukemia. 2020;34:1090\u2013101.","journal-title":"Leukemia."},{"key":"1958_CR54","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1002\/ajh.24075","volume":"90","author":"J Schwaab","year":"2015","unstructured":"Schwaab J, Umbach R, Metzgeroth G, Naumann N, Jawhar M, Sotlar K, et al. KIT D816V and JAK2 V617F mutations are seen recurrently in hypereosinophilia of unknown significance. Am J Hematol. 2015;90:774\u20137.","journal-title":"Am J Hematol"},{"key":"1958_CR55","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1111\/bjh.15061","volume":"183","author":"A Tefferi","year":"2018","unstructured":"Tefferi A, Shah S, Mudireddy M, Lasho TL, Barraco D, Hanson CA, et al. Monocytosis is a powerful and independent predictor of inferior survival in primary myelofibrosis. Br J Haematol. 2018;183:835\u20138.","journal-title":"Br J Haematol"},{"key":"1958_CR56","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1002\/ajh.24740","volume":"92","author":"D Barraco","year":"2017","unstructured":"Barraco D, Cerquozzi S, Gangat N, Patnaik MM, Lasho T, Finke C, et al. Monocytosis in polycythemia vera: clinical and molecular correlates. Am J Hematol. 2017;92:640\u20135.","journal-title":"Am J Hematol"},{"key":"1958_CR57","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1097\/MD.0b013e3182a71eba","volume":"92","author":"F Legrand","year":"2013","unstructured":"Legrand F, Renneville A, MacIntyre E, Mastrilli S, Ackermann F, Cayuela JM, et al. The spectrum of FIP1L1-PDGFRA-associated chronic eosinophilic leukemia: new insights based on a survey of 44 cases. Medicine (Baltimore). 2013;92:e1\u2013e9.","journal-title":"Medicine (Baltimore)"},{"key":"1958_CR58","doi-asserted-by":"publisher","first-page":"1314","DOI":"10.1002\/ajh.25945","volume":"95","author":"J Rohmer","year":"2020","unstructured":"Rohmer J, Couteau-Chardon A, Trichereau J, Panel K, Gesquiere C, Ben Abdelali R, et al. Epidemiology, clinical picture and long-term outcomes of FIP1L1-PDGFRA-positive myeloid neoplasm with eosinophilia: Data from 151 patients. Am J Hematol. 2020;95:1314\u201323.","journal-title":"Am J Hematol"},{"key":"1958_CR59","doi-asserted-by":"publisher","first-page":"2239","DOI":"10.1182\/blood-2011-03-343426","volume":"118","author":"C Walz","year":"2011","unstructured":"Walz C, Erben P, Ritter M, Bloor A, Metzgeroth G, Telford N, et al. Response of ETV6-FLT3-positive myeloid\/lymphoid neoplasm with eosinophilia to inhibitors of FMS-like tyrosine kinase 3. Blood. 2011;118:2239\u201342.","journal-title":"Blood."}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41375-023-01958-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-023-01958-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-023-01958-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,25]],"date-time":"2023-08-25T09:03:32Z","timestamp":1692954212000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41375-023-01958-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,15]]},"references-count":59,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2023,9]]}},"alternative-id":["1958"],"URL":"https:\/\/doi.org\/10.1038\/s41375-023-01958-1","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,15]]},"assertion":[{"value":"12 October 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 May 2023","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 June 2023","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 July 2023","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}